[Antipsychotic efficacy of neuroleptic neuropeptides in schizophrenia. Review of clinical data].

Abstract

Recently much interest has been shown in the antipsychotic efficacy of neuroleptic-like neuropeptides in schizophrenia. In this article the clinical effects of the non-opioid fragments of gamma-endorphin, the so-called gamma-type endorphins DT gamma E and DE gamma E are reviewed. In addition, preliminary clinical studies of peptides related to cholecystokinin are considered. It is concluded that gamma-type endorphins possess antipsychotic properties in a subgroup of patients who may belong to Type I schizophrenia. With cholecystokinin-related peptides, in particular ceruletide, antipsychotic effects have been reported, which seem to be more or less comparable to those observed with gamma-type endorphins.

• Authors: V M Verhoeven
• Journal: L'Encephale (Encephale) 1987 Nov-Dec Vol. 13 Issue 6 Pg. 349-56 ISSN: 0013-7006 [Print] France
• Vernacular Title: Efficacité antipsychotique des neuropeptides neuroleptiques dans la schizophrénie. Revue des données cliniques.
• PMID: 2453339 (Publication Type: Comparative Study, English Abstract, Journal Article, Review)

Chemical References

• Antipsychotic Agents
• Endorphins
• gamma-Endorphin
• Cholecystokinin

Topics

• Antipsychotic Agents (therapeutic use)
• Cholecystokinin (therapeutic use)
• Endorphins (therapeutic use)
• Humans
• Schizophrenia (drug therapy)
• Schizophrenia, Disorganized (drug therapy)
• Schizophrenia, Paranoid (drug therapy)
• gamma-Endorphin